Stockreport

Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial [Yahoo! Finance]

Repare Therapeutics Inc. - Common Shares  (RPTX) 
PDF precision oncology company, today announced the first patient has been dosed in the Company's camonsertib monotherapy non-small cell lung cancer (NSCLC) expansion of the [Read more]